Losartan Potassium
Product Images NDC 50090-4255

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 50090-4255). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500904255)

Losartan Potassium label by A-S Medication Solutions, NDC 50090-4255, containing 90 tablets. The label indicates each tablet contains Losartan Potassium USP 25 mg. Storage instructions specify to store at 68 to 77 degrees Fahrenheit and protect from light. The label also includes lot number, expiration date, and a barcode.*

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

Chemical structure of Losartan Potassium, depicting its molecular arrangement including the chlorinated pyrimidine ring, hydroxymethyl side group, biphenyl moiety, and potassium ion.*

FDA Label Image

Figure 1 (Spl Image2 Figure1)

A line graph comparing the percentage of patients with a primary endpoint over time between Atenolol (dotted line) and Losartan Potassium (solid line). The x-axis represents the study month from 0 to 66, and the y-axis shows the percentage of patients from 0% to 16%. A note indicates an adjusted risk reduction of 13% with a p-value of 0.021 for Losartan Potassium.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months for Atenolol (dotted line) and Losartan Potassium (solid line). The graph shows adjusted risk reduction of 25% with a p-value of 0.001, indicating statistical significance over 66 months.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

A forest plot figure titled 'Primary Endpoint Events within Demographic Subgroups' comparing Losartan Potassium and Atenolol. It shows hazard ratios and event rates (%) for overall results and subgroups by age, gender, race, ISH, diabetes, and history of CVD. The figure includes two primary outcome categories: Primary Composite and Stroke (Fatal/Non-fatal), with symbols proportional to sample size. The x-axis ranges from 0.3 to 3, indicating favor towards either Losartan Potassium or Atenolol.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

A line graph comparing the percentage of patients with events over 48 months between Losartan Potassium and Placebo groups. The Y-axis represents the percentage of patients with events, and the X-axis shows time in months. The graph indicates a risk reduction of 16.1% with Losartan Potassium versus placebo with statistical significance (p=0.022).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.